Precision Medicine And Late-stage Trials Will Expand Global Reach
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 19 Analysts
Published
10 Aug 25
Updated
10 Aug 25
AnalystConsensusTarget's Fair Value
US$71.95
47.4% undervalued intrinsic discount10 Aug
US$37.84
1Y
-33.4%7D
10.3%